EUCTR2012-003633-42-GB进行中（未招募）不适用
A randomized, double blind controlled trial comparing rituximab against intravenous cyclophosphamide in connective tissue disease associated interstitial lung disease - Rituximab versus cyclophosphamide in connective tissue disease-ILD
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects will be recruited prospectively from rheumatology or interstitial lung disease units at 6 UK centres. Prior to enrolment potential study subjects will be assessed according to the following inclusion and exclusion criteria; Inclusion Criteria: • A diagnosis of connective tissue disease, based on internationally accepted criteria, in one of the following categories: o Systemic sclerosis o Idiopathic interstitial myopathy (including polymyositis/dermatomyositis) o Mixed connective tissue disease • Severe and/or progressive interstitial lung disease associated with the underlying connective tissue disease. • Chest HRCT performed within 12 months of randomisation • Intention of the caring physician to treat the ILD with intravenous cyclophosphamide (with treatment indications including deteriorating symptoms attributable to ILD, deteriorating lung function tests, worsening gas exchange or extent of ILD at first presentation)and where there is a reasonable expectation that immunosuppressive treatment will stabilize or improve CTD-ILD • Written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 80
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 36
排除标准
- •Exclusion Criteria: • Age <18 or >80 years. • Previous treatment with Rituximab and/or intravenous Cyclophosphamide • Known hypersensitivity to Rituximab or Cyclophosphamide or their components • Significant (in the opinion of the investigator) other organ co-morbidity including cardiac, hepatic or renal impairment • Co-existent obstructive pulmonary disease (e.g. asthma, COPD, emphysema) with pre bronchodilator FEV1/FVC < 70% • Patients at significant risk for infectious complications following immunosuppression including HIV positive or other immunodeficiency syndromes (including hypogammaglobulineamia) • Suspected or proven untreated tuberculosis • Viral hepatitis • Infection requiring antibiotic treatment in the preceding four weeks • Unexplained neurological symptoms (which may be suggestive of progressive mutifocal leukoencephalopathy; PML). Neurological symptoms arising as a consequence of the underlying CTD do not necessitate exclusion. • Other investigational therapy (participation in research trial) received within 8 weeks of randomisation • Immunosuppressive or CTD disease modifying therapy (other than corticosteroids) received within 2 weeks of randomisation • Pregnant or breast feeding women, or women of child-bearing potential, not using a reliable contraceptive method for up to 12 months following IMP • Unexplained haematuria, or previous bladder carcinoma • CT scan > 12 months from randomisation • Unable to provide informed written consent
研究者
相似试验
招募中
不适用
A double blind randomized controlled trial comparing the efficacy of 7% lidocaine / 7% tetracaine cream versus 2,5% lidocaine / 2,5% prilocaine cream for local anaesthesia during laser treatment of acne keloidalis nuchae and tattoo removal.2. acne keloidalis nuchaelaser treatment of: 1. tattoos10040798NL-OMON41973Erasmus MC, Universitair Medisch Centrum Rotterdam30
进行中（未招募）
不适用
A double blind randomized controlled trial comparing the efficacy of two anaesthetic creams for local anaesthesia during laser treatment.Pain during laser treatment of:1. Tattoo 2. Acne keloidalis nuchaeEUCTR2014-003610-86-NL
已完成
3 期
A double-blind randomized controlled trial comparing 0.75mg of Palonosetron with 1mg of Granisetron for the control of highly emetogenic chemotherapy-induced emesis.Malignant tumor (lung cancer,gastric cancer,esophagus cancer,cervical cancer,endometrial cancer,head and neck cancer,etc)JPRN-UMIN000004863Pharma Valley Center,Shizuoka Organization for Creation Industries840
已完成
3 期
A double-blind randomized controlled trial comparing 3mg and 1mg of ranisetron for the control of chemotherapy-induced acute emesisMalignant tumor (breast cancer, lung cancer, gastric cancer, esophagus cancer, colorectal cancer, etc)JPRN-UMIN000000984Pharma Valley Center, Shizuoka Organization for Creation Industries360
已完成
不适用
A double-blind randomized controlled trial comparing PArietene self-fixing semi-Resorbable mesh with standard heavy-weight polypropylene mesh on chronic inguinal pAin DEvelopmentChronic pain after inguinal hernia repair10041297NL-OMON31651Tyco Health Care350